Mitsubishi Tanabe Pharma closed a stock transfer agreement to acquire the Stelic Institute & Co., that will split prior to the acquisition into the intestinal disease business and other business. Stelic’s intestinal disease pipeline includes STNM01, a siRNA pharmaceutical administered via submucosal injection through an endoscope. The product is under development for ulcerative colitis in Germany and Crohn’s disease in Japan.



Please enter your comment!
Please enter your name here